Microsphere formulations comprising ketamine and methods for making and using the same
Extended-release, injectable microsphere formulations comprising ketamine are provided. Methods for making and using the microsphere formulations are also provided.
1. A microsphere formulation, comprising:
polymer microspheres, each polymer microsphere comprising:
esketamine in a concentration of about 10 wt/wt % to about 30 wt/wt %; and
a biodegradable poly(lactide) polymer in a concentration of about 70 wt/wt % to about 90 wt/wt %, wherein the biodegradable poly(lactide) polymer has an inherent viscosity from about 0.6 dL/g to about 0.7 dL/g;
wherein the polymer microspheres have a particle size greater than 60 μm (D 50 );
wherein the polymer microspheres are characterized in that each of the polymer microspheres comprises an internal polymer phase, a plurality of internal macrovoids dispersed within the internal polymer phase, and an outer surface substantially free of voids; and
wherein the polymer microspheres are prepared by a method that does not include the use of a porogen, the method comprising:
(i) contacting the esketamine with the biodegradable poly(lactide) polymer in the presence of a solvent to form an organic component;
(ii) emulsifying an inner aqueous component comprising water with the organic component to form a primary emulsion;
(iii) emulsifying the primary emulsion with a continuous phase comprising water to form a secondary emulsion;
(iv) removing the solvent from the secondary emulsion to form the polymer microspheres; and
(v) subjecting the polymer microspheres to dehydration.
2. The microsphere formulation of claim 1 , wherein the polymer microspheres have a particle size of about 70 μm (D 50 ) to about 110 μm (D 50 ).
3. The microsphere formulation of claim 1 , wherein each polymer microsphere has an esketamine concentration of between about 12 wt/wt % to about 17 wt/wt % and a biodegradable poly(lactide) polymer concentration of about 83 wt/wt % to about 88 wt/wt %.
4. The microsphere formulation of claim 1 , characterized in that about 75% to 100% of the esketamine is released over a period of between about 25 to about 35 days of injection into a human subject, but not more than about 10% of the esketamine has been released within 24 hours of injection into the human subject.
5. A pharmaceutical composition comprising the microsphere formulation of claim 1 .
6. The microsphere formulation of claim 1 , wherein each of the polymer microspheres is further characterized in that the esketamine is dispersed within the internal polymer phase.